Complex Regional Pain Syndromes Pipeline, Clinical Trials, and Key Companies | Companies – Takeda, Soin Therapeutics, Tryp Therapeutics
DelveInsight Business Research LLP
(United States, Nevada, Las Vegas), DelveInsight’s “Complex regional pain syndromes- Pipeline Insight, 2023” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Complex regional pain syndromes pipeline landscape.

(United States, Nevada, Las Vegas), DelveInsight’s “Complex regional pain syndromes- Pipeline Insight, 2023Pipeline Insight, 2023” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Complex regional pain syndromes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Complex Regional Pain Syndromes Pipeline Report

  • Over 3+ companies and 3+ pipeline drugs in Complex Regional Pain Syndromes are in various stages of development, and their anticipated acceptance in the Complex Regional Pain Syndromes market would significantly increase market revenue. 

  • Leading Complex Regional Pain Syndromes companies developing novel drug candidates to improve the Complex Regional Pain Syndromes treatment landscape include TakedaTryp Therapeutics, Soin Therapeutics, and many others.

  • Promising Complex Regional Pain Syndromes pipeline therapies in various stages of development include TRP-8803, Soticlestat, and many others.

Complex Regional Pain Syndromes Overview

Complex regional pain syndrome (CRPS) is a term for a variety of clinical conditions characterized by chronic persistent pain and is subdivided into Type I and Type II CRPS. It is a condition that can develop after a limb trauma and appears mostly in one or more limbs. CRPS can be considered a regional post-traumatic neuropathic pain problem, and like other neuropathic pain disorders, symptoms are a disproportionate consequence of painful trauma or nerve lesion. Magnetic resonance imaging (MRI) can also be used to determine if tissue changes typical of CRPS and specialized magnetic resonance neurography can be used to evaluate for specific nerve involvement. CRPS has no cure. Treatment is most effective when started early and focuses on relieving symptoms, slowing the progression of the disease, and helping sufferers cope with the pain and lead as healthy lives as possible.

Complex Regional Pain Syndromes Pipeline, Clinical Trials, and Key Companies | Companies – Takeda, Soin Therapeutics, Tryp Therapeutics 1

Complex Regional Pain Syndromes Pipeline Analysis: Drug Profile

Soticlestat: Takeda

Soticlestat is a novel, first-in-class therapy designed and developed as a selective CH24H inhibitor with the potential to reduce seizure susceptibility and improve seizure control1. In February 2022, the Minister of Health, Labour, and Welfare granted an orphan drug designation for soticlestat as a potential treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), both of which are developmental epileptic encephalopathies (DEEs), designated as intractable diseases in Japan. The Breakthrough Award from the Pharmaceutical Society of Japan recognizes Takeda’s research as contributing to the advancement of drug discovery research through the unique approaches taken to developing an innovative drug with a novel chemical structure. Takeda won this award for the first time in 9 years, marking its sixth win. Currently, the drug is in the Phase II stage of Clinical trial evaluation for the treatment of Complex Regional Pain Syndrome.

TRP-8803: Tryp Therapeutics

TRP-8803, a proprietary, psilocybin-based drug is manufactured exclusively for Tryp by Curia and Alcami and features a novel route of administration. Currently, the drug is in the Preclinical stage of development for the treatment of Complex Regional Pain Syndrome.

Discover more about the emerging Complex Regional Pain Syndromes drugs @ Complex Regional Pain Syndromes Treatment Drugs

Complex Regional Pain Syndromes  Pipeline Therapies and Key Companies

  • Soticlestat: Takeda

  • TRP-8803: Tryp Therapeutics

And many others 

DelveInsight’s Report covers around 33+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Complex Regional Pain Syndromes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

 

Molecule Type

 

Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Scope of the Complex Regional Pain Syndromes Pipeline Report 

  • Coverage: Global 

  • Key Complex Regional Pain Syndromes  Companies: Takeda, Tryp Therapeutics, Soin Therapeutics, and many others 

  • Key Complex Regional Pain Syndromes Pipeline Therapies: Soticlestat, TRP-8803, and many others.

Find out more about the Complex Regional Pain Syndromes treatment options in development @ Complex Regional Pain Syndromes  Clinical Trials

Table of Contents

1. Complex Regional Pain Syndromes Introduction

2. Complex Regional Pain Syndromes Executive Summary

3. Complex Regional Pain Syndromes Overview

4. Complex Regional Pain Syndromes Pipeline Therapeutics

5. Complex Regional Pain Syndromes Late-Stage Products (Phase III)

6. Complex Regional Pain Syndromes Mid-Stage Products (Phase  II)

7. Complex Regional Pain Syndromes Early Stage Products (Phase  I/II)

8. Complex Regional Pain Syndromes Preclinical Stage Products

9. Complex Regional Pain Syndromes Discovery Stage Products

10. Complex Regional Pain Syndromes Therapeutic Assessment

11. Complex Regional Pain Syndromes Inactive Products

12. Complex Regional Pain Syndromes Collaborations Assessment- Licensing / Partnering / Funding

13. Complex Regional Pain Syndromes Unmet Needs

14. Complex Regional Pain Syndromes Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Leave a Reply

Your email address will not be published. Required fields are marked *